Trump announces efforts to expand access to IVF drugs

President Donald Trump announced two initiatives aimed at expanding in vitro fertilization (IVF) access and reducing its high costs. This includes a deal with EMD Serono, a Merck KGaA subsidiary and leading fertility drug manufacturer, to significantly cut prices on key IVF medications like Gonal-f in exchange for tariff relief, with direct-to-consumer sales expected via TrumpRx.gov by January 2026. Concurrently, new guidance will encourage employers to offer fertility benefits, though this is not a mandate. These measures seek to address the substantial financial burden of IVF, which can exceed $20,000 per cycle and is often not fully covered by insurance, making it considerably more expensive in the U.S. than in other nations.

Analysis

President Trump's administration has initiated two key efforts to address the high cost and limited accessibility of in vitro fertilization (IVF) in the U.S., a procedure costing over $20,000 per cycle and significantly more than in other developed nations. A deal with EMD Serono, a subsidiary of Germany's Merck KGaA and the world's largest fertility drug manufacturer, aims to substantially reduce prices for critical IVF medications like Gonal-f. This agreement provides EMD Serono relief from potential pharmaceutical tariffs in exchange for direct-to-consumer sales via the upcoming TrumpRx.gov platform, slated for launch in January 2026.

Concurrently, new guidance will encourage employers to offer fertility benefits, similar to vision or dental coverage, allowing for add-on coverage at a fixed cost. However, the impact on coverage expansion remains uncertain as employer participation is not mandated, and currently, only a quarter of companies with over 200 employees provide IVF coverage. This initiative aligns with Trump's broader agenda to rein in prescription drug costs, following similar deals with Pfizer and AstraZeneca.

The moves are positioned to address a politically significant issue, with Trump having previously vowed to make IVF more accessible, and public support for IVF access standing at 70% according to an April 2024 Pew Research Center poll. While the administration previously issued an executive order on IVF without specific follow-through, these new actions represent concrete steps. The context of the Alabama Supreme Court ruling on frozen embryos also highlights the political sensitivity and public demand for IVF access protection.

The direct-to-consumer model for fertility drugs and the encouragement of employer benefits could significantly alter the landscape for fertility treatment providers and drug distributors. The tariff relief aspect for EMD Serono also underscores the administration's use of trade policy as leverage in healthcare cost negotiations. The overall sentiment is moderately positive, reflecting the potential for increased access and reduced costs, though the market impact is currently assessed as moderate.

Key Decisions for Investors

• Investors should monitor the implementation and adoption rates of TrumpRx.gov for direct-to-consumer fertility drug sales, as this could shift market dynamics for pharmaceutical distributors and pharmacies.
• Evaluate the potential revenue impact on Merck KGaA's EMD Serono division from increased volume due to lower prices and tariff relief, balanced against potential margin compression.
• Assess the long-term implications for healthcare benefit providers and fertility clinic networks if employer-sponsored fertility benefits gain significant traction, despite the non-mandated nature of the guidance.